Niels Jongs - Concepedia

Author

Niels Jongs

University of Groningen ORCID

Also Known As

Jongs, N, Jongs, Niels, N Jongs, N. Jongs, NIELS JONGS, Niels Jongs

124

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of Groningen University Medical Center Groningen The George Institute for Global Health AstraZeneca (Sweden)Stanford University

About

Niels Jongs is an author at University of Groningen specializing in medicine, chronic kidney disease, and renal disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	966
2	Diabetes	4	4	942
3	Nephrology	3	3	392
4	Pharmacology	3	3	598
5	Health Sciences	1	1	76

Niels Jongs

Publications

Citations

H-Index

Page 1

	Year	Citations
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, The Lancet Diabetes & Endocrinology Metabolic SyndromeHypertensionRenal FunctionRenal DiseaseCardiovascular Disease	2020	498
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Kidney International	2021	369
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial Niels Jongs, Tom Greene, Glenn M. Chertow, The Lancet Diabetes & Endocrinology UrologyRenal DiseaseRenal FunctionKidney FailureDiabetes	2021	187
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, The Lancet Diabetes & Endocrinology Metabolic SyndromeRenal FunctionRenal DiseaseKidney FailureDiabetes	2021	181
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial Michele Provenzano, María Jesús Puchades, Carlo Garofalo, Journal of the American Society of Nephrology	2022	163
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Circulation	2020	138
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, European Heart Journal	2021	118
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, JACC Heart Failure	2021	101
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease Priya Vart, Niels Jongs, Ricardo Correa‐Rotter, UCL Discovery (University College London)	2021	101
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial David C. Wheeler, Niels Jongs, Bergur V. Stefánsson, Nephrology Dialysis Transplantation	2021	88

Page 1